Beta Drugs Ltd. Submits Integrated Financial Filing for December Quarter 2024

Team Finance Saathi

25/Jan/2025

What's covered under the Article:

Beta Drugs Ltd. complies with SEBI and NSE filing requirements for the December 2024 quarter.
The company clarifies no deviations in the use of raised funds during the December quarter.
No defaults on loans or debt securities, and no related party transactions are reported.

Beta Drugs Ltd. has complied with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 and NSE Circular No. NSE/CML/2025/02, submitting their Integrated Financial Filing for the quarter ending December 31, 2024. The company, listed on the SME platform, has followed the required protocols outlined in the SEBI and NSE circulars, reflecting its commitment to transparency and regulatory adherence.

The filing includes the Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, and more. Beta Drugs Ltd. has confirmed that no deviations in the use of raised funds have occurred during the quarter, ensuring that all fundraising activities are in line with the original objectives disclosed to shareholders.

Additionally, there have been no defaults on loans and debt securities as of December 31, 2024. The company has not reported any related party transactions, as it is only required to disclose these on a half-yearly basis (2nd and 4th quarter filings).

The filing also touches on the Statement on Impact of Audit Qualifications; however, no audit qualifications or modifications are applicable to the current filing, as it is not the annual filing. As the company is listed on the SME platform, certain disclosures, such as those related to financial results, are not applicable.

It is important to note that Beta Drugs Ltd. continues to adhere to the rules and regulations laid out by the regulatory authorities and demonstrates a commitment to strong corporate governance. This filing is a critical part of their transparency and business operations in alignment with the public interest.

For more Real-time Updates, Bookmark https://financesaathi.com

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.

Join our Finance Saathi Telegram Channel for Regular Share Market, News & IPO Updates.

Disclaimer

The information provided on this website is for educational and informational purposes only and should not be considered as financial advice, investment advice, or trading recommendations.

Trading in stocks, forex, commodities, cryptocurrencies, or any other financial instruments involves high risk and may not be suitable for all investors. Prices can fluctuate rapidly, and there is a possibility of losing part or all of your invested capital.

We do not guarantee any profits, returns, or outcomes from the use of our website, services, or tools. Past performance is not indicative of future results.

You are solely responsible for your investment and trading decisions. Before making any financial commitment, it is strongly recommended to consult with a qualified financial advisor or do your own research.

By accessing or using this website, you acknowledge that you have read, understood, and agree to this disclaimer. The website owners, partners, or affiliates shall not be held liable for any direct or indirect loss or damage arising from the use of information, tools, or services provided here.

Services

Beta Drugs Ltd. Submits Integrated Financial Filing for December Quarter 2024

Related News

Disclaimer